New dopaminergic agonists

被引：0

作者：

De Mattos, JP ^{[1
]}

Mattos, VMDC ^{[1
]}

机构：

[1] Univ Fed Rio de Janeiro, Serv Neurol, Hosp Univ Clementino Fraga Filho, BR-21941 Rio De Janeiro, Brazil

来源：

ARQUIVOS DE NEURO-PSIQUIATRIA | 1999年 / 57卷 / 2A期

关键词：

levodopa; dopaminergic agonists; Parkinson's disease;

D O I：

10.1590/S0004-282X1999000200029

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

We present a brief review of the literature about dopaminergic a,agonists. We report the five known dopaminergic receptors, where they are located, the advantages and disadvantages of the employment in parkinsonian patients. The dopaminergic agonists were introduced to control the limitations of levodopa-increasing the therapheutic window. We analyse the pharmacocynetic efficacy and the side effects of cabergoline, ropinirole and pramipexole.

引用

页码：329 / 332

页数：4

共 50 条

[21] Combinatorial topography and cell-type specific regulation of the ERK pathway by dopaminergic agonists in the mouse striatum
Gangarossa, Giuseppe
Perroy, Julie
Valjent, Emmanuel
BRAIN STRUCTURE & FUNCTION, 2013, 218 (02) : 405 - 419
[22] Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice
Olson, Katherine E.
Kosloski-Bilek, Lisa M.
Anderson, Kristi M.
Diggs, Breha J.
Clark, Barbara E.
Gledhill, John M., Jr.
Shandler, Scott J.
Mosley, R. Lee
Gendelman, Howard E.
JOURNAL OF NEUROSCIENCE, 2015, 35 (50) : 16463 - 16478
[23] Dopaminergic therapy in aphasia
Gill, Sumanjit K.
Leff, Alexander P.
APHASIOLOGY, 2014, 28 (02) : 155 - 170
[24] Pilot study of a new tool to optimise dopaminergic treatment in Parkinson's disease: the OPTIMIPARK questionnaire
Manez-Miro, Jorge U.
Vivancos-Matellano, Francisco
Wetmore, John B.
Martinez-Martin, Pablo
REVISTA DE NEUROLOGIA, 2021, 72 (06) : 179 - 186
[25] Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials
Shrateh, Oadi N.
Kumar, Kanwal Ashok
Jawed, Areesha
Shuja, Muhammad Hamza
Shamsi, Hammad Ur Rehman
Naasan, Mashhour
JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2024, 53 (06)
[26] Combination of group I mGlu receptors antagonist with dopaminergic agonists strengthens the synaptic transmission at corticostriatal synapses in culture
Burguiere, Adeline
De Bundel, Dimitri
Valjent, Emmanuel
Roger, Jonathan
Smolders, Ilse
Fagni, Laurent
Perroy, Julie
NEUROPHARMACOLOGY, 2013, 66 : 151 - 157
[27] Circulating prolactin levels and the effect of dopaminergic agonists in systemic lupus erythematosus: a systematic review and meta-analysis
dos Santos, alida Alves
de Castro, Lucas Faria
de Lima, Caroline Lourenco
da Motta, Lucilia Domingues Casulari
da Motta, Luiz Augusto Casulari Roxo
Amato, Angelica Amorim
SCIENTIFIC REPORTS, 2024, 14 (01):
[28] Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease
Steiger, M.
EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (01) : 2 - 11
[29] Dopaminergic dysfunction in Parkinsonism: New lessons from imaging
Marek, K
NEUROSCIENTIST, 1999, 5 (05) : 333 - 340
[30] Dopomine agonists in the future - clinical trials of new medications
Jasinska-Myga, Barbara
Opala, Grzegorz
NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2007, 41 (02) : S49 - S53

← 1 2 3 4 5 →